Stent fractures in the superficial femoral artery: predisposing factors and their implications
Fraturas de stents na artéria femoral superficial: fatores predisponentes e suas implicações
Fernando Trés Silveira; Álvaro Razuk Filho; Paulo Fernandes Saad; Karen Ruggeri Saad; Gustavo José Politzer Telles; Pedro Ivo C. Ravizzini; Roberto Augusto Caffaro; Valter Castelli Júnior
Abstract
Keywords
Resumo
Resumo:
Palavras-chave
Referências
1 Adlakha S, Sheikh M, Wu J, et al. Stent fracture in the coronary and peripheral arteries. J Interv Cardiol. 2010;23(4):411-9.
2 Ferreira M, Capotorto LF, Abuhadba G, Monteiro M, Lanziotti L. Recanalização da artéria femoral superficial com stents Zilver: técnica padronizada e análise retrospectiva de 3 anos. J Vasc Bras. 2006;5(4):263-70.
3 Laird J. Interventional options in the SFA. Endovasc Today. 2004;(Suppl.):9-12.
4 Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106(12):1505-9.
5 Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from de SIROCCO trial. J Endovasc Ther. 2006;13(6):701-10.
6 Canan T, Lee MS. Drug-eluting stent fracture: incidence, contributing factors, and clinical implications. Catheter Cardiovasc Interv. 2010;75(2):237-45.
7 Andrassy M, Celik S, Andrassy J, Lichtenberg MK, Brodmann M. The role of drug-coated balloons in in-stent restenosis. J Cardiovasc Surg. 2017;58(4):501-7.
8 Deloose K, Callaert J. Less is more: the “As Less As Reasonably Achievable Stenting” (ALARAS) strategy in the femoropopliteal area. J Cardiovasc Surg. 2018;59(4):495-503.
9 Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16(3):331-8.
10 Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoroplopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology. 2004;232(2):516-21.
11 Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12(1):6-12.
12 Allie DE, Hebert CJ, Ricis RT, Walker CGM. Nitinol stent fractures in the SFA. Endovasc. Today. 2004;7:22-34.
13 Iida O, Nanto S, Uematsu M, et al. Effects of exercise on frequency of stent fracture in the superficial femoral artery. Am J Cardiol. 2006;98(2):272-4.
14 Gouëffic Y, Kaladji A. Commentary: the clinical relevance of superficial femoral artery stent fractures remains obscure. J Endovasc Ther. 2015;22(3):327-9.
15 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(1, Suppl. S):S5-67.
16 Schlager O, Dick P, Sabeti S, et al. Long-segment SFA stenting–The dark sides: In-stent restenoses, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12(6):676-84.
17 Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Nagata S. Influence of stent fracture on the long-term patency in the femoro-popliteal artery. JACC Cardiovasc Interv. 2009;2(7):665-71.
18 Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expansible nitinol stent. J Vasc Surg. 2010;52(3):608-15.
19 Iida O, Soga Y, Hirano K, et al. Retrospective multicentre analysis of S.M.A.R.T vs. Luminexx nitinol stent implantation for superficial femoral artery lesions (REAL SL) Registry: 5 years’ experience. Circ J. 2011;75(2):421-7.
20 Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty vs. implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879-88.
21 Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312-5.
22 Klein AJ, Chen SJ, Messenger JC, et al. Quantitative assessment of conformational change in the femoropopliteal artery with leg movement. Catheter Cardiovasc Interv. 2009;74(5):787-98.
23 Ganguly A, Simons J, Schneider A, Keck B, Bennett NR, Fahrig R. In-vitro imaging of femoral artery nitinol stents for deformation analysis. J Vasc Interv Radiol. 2011;22(2):236-43.
24 Pelton AR, Schroeder V, Mitchell MR, Gong XY, Barney M, Robertson SW. Fatigue and durability of nitinol stents. J Mech Behav Biomed Mater. 2008;1(2):153-64.
25 Alzamora MT, Forés R, Baena-Diez JM, et al. The peripheral arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population. BMC Public Health. 2010;10(1):38.
26 Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79(4):541-8.
Submetido em:
03/03/2020
Aceito em:
23/09/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email